Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Schultz CW, Zhang Y, Elmeskini R, Zimmermann A, Fu H, Murai Y, Wangsa D, Kumar S, Takahashi N, Atkinson D, Saha LK, Lee CF, Elenbaas B, Desai P, Sebastian R, Sharma AK, Abel M, Schroeder B, Krishnamurthy M, Kumar R, Roper N, Aladjem M, Zenke FT, Ohler ZW, Pommier Y, Thomas A. Schultz CW, et al. Among authors: elenbaas b. EMBO Mol Med. 2023 Aug 7;15(8):e17313. doi: 10.15252/emmm.202217313. Epub 2023 Jul 25. EMBO Mol Med. 2023. PMID: 37491889 Free PMC article.
Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko A, Zhang L, Le Brazidec JY, Fan J, Chong JH, Hingway A, Raditsis A, Singh L, Elenbaas B, Hong VS, Marcotte D, Silvian L, Enyedy I, Chao J. Ishchenko A, et al. Among authors: elenbaas b. Bioorg Med Chem Lett. 2015 Feb 1;25(3):474-80. doi: 10.1016/j.bmcl.2014.12.041. Epub 2014 Dec 19. Bioorg Med Chem Lett. 2015. PMID: 25575657
Author Correction: ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Schultz CW, Zhang Y, Elmeskini R, Zimmermann A, Fu H, Murai Y, Wangsa D, Kumar S, Takahashi N, Atkinson D, Saha LK, Lee CF, Elenbaas B, Desai P, Sebastian R, Sharma AK, Abel M, Schroeder B, Krishnamurthy M, Bassel LL, Kumar R, Roper N, Aladjem M, Zenke FT, Ohler ZW, Pommier Y, Thomas A. Schultz CW, et al. Among authors: elenbaas b. EMBO Mol Med. 2024 Mar;16(3):664. doi: 10.1038/s44321-024-00029-x. EMBO Mol Med. 2024. PMID: 38366163 Free PMC article.
p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab.
Fukuoka S, Koga Y, Yamauchi M, Koganemaru S, Yasunaga M, Shitara K, Doi T, Yoshino T, Kuronita T, Elenbaas B, Wahra P, Zhang H, Crowley L, Jenkins MH, Clark A, Kojima T. Fukuoka S, et al. Among authors: elenbaas b. Sci Rep. 2023 Sep 25;13(1):16017. doi: 10.1038/s41598-023-40612-9. Sci Rep. 2023. PMID: 37749105 Free PMC article.
MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.
Vena F, Jia R, Esfandiari A, Garcia-Gomez JJ, Rodriguez-Justo M, Ma J, Syed S, Crowley L, Elenbaas B, Goodstal S, Hartley JA, Hochhauser D. Vena F, et al. Among authors: elenbaas b. Oncotarget. 2018 Jan 22;9(14):11592-11603. doi: 10.18632/oncotarget.24294. eCollection 2018 Feb 20. Oncotarget. 2018. PMID: 29545922 Free PMC article.
Human IAPP is a contributor to painful diabetic peripheral neuropathy.
Albariqi MM, Versteeg S, Brakkee EM, Coert JH, Elenbaas BO, Prado J, Hack CE, Höppener JW, Eijkelkamp N. Albariqi MM, et al. Among authors: elenbaas bo. J Clin Invest. 2023 Apr 17;133(8):e156993. doi: 10.1172/JCI156993. J Clin Invest. 2023. PMID: 36917177 Free PMC article.
28 results